Literature DB >> 7776456

Hematuria home screening: repeat testing results.

E M Messing1, T B Young, V B Hunt, M A Newton, L L Bram, A Vaillancourt, W J Hisgen, E B Greenberg, M E Kuglitsch, J D Wegenke.   

Abstract

To determine at what interval screening should be repeated to detect bladder cancer before it becomes muscle invasive 856 men who had 14 negative daily home tests for hematuria with a chemical reagent strip 9 months previously performed repeat tests. Of these men 50 (5.8%) had at least 1 positive test during the second 14-day screening period and 38 were evaluated, 15 of whom (39.5%) had significant urological pathological conditions, including 8 with malignancies. Bladder cancer was noted in 7 men, with no tumor invading the muscularis propria. The finding of 7 bladder cancers in 856 men (0.82%) who had a negative test 9 months previously indicates that bladder cancer has a brief preclinical duration and that testing must be repeated at least annually for screening to detect bladder cancer consistently before invasion occurs.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7776456     DOI: 10.1016/s0022-5347(01)67224-0

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  16 in total

Review 1.  Time to abandon testing for microscopic haematuria in adults?

Authors:  Per-Uno Malmström
Journal:  BMJ       Date:  2003-04-12

Review 2.  Is there a rationale for bladder cancer screening?

Authors:  Robert S Svatek; Yair Lotan
Journal:  Curr Urol Rep       Date:  2008-09       Impact factor: 3.092

3.  Quality of care in patients with bladder cancer: a case report?

Authors:  Karim Chamie; Christopher S Saigal; Julie Lai; Jan M Hanley; Claude M Setodji; Badrinath R Konety; Mark S Litwin
Journal:  Cancer       Date:  2011-08-05       Impact factor: 6.860

4.  High-risk patients with hematuria are not evaluated according to guideline recommendations.

Authors:  Keren Elias; Robert S Svatek; Samir Gupta; Richard Ho; Yair Lotan
Journal:  Cancer       Date:  2010-06-15       Impact factor: 6.860

5.  Recommendations for the improvement of bladder cancer quality of care in Canada: A consensus document reviewed and endorsed by Bladder Cancer Canada (BCC), Canadian Urologic Oncology Group (CUOG), and Canadian Urological Association (CUA), December 2015.

Authors:  Wassim Kassouf; Armen Aprikian; Peter Black; Girish Kulkarni; Jonathan Izawa; Libni Eapen; Adrian Fairey; Alan So; Scott North; Ricardo Rendon; Srikala S Sridhar; Tarik Alam; Fadi Brimo; Normand Blais; Chris Booth; Joseph Chin; Peter Chung; Darrel Drachenberg; Yves Fradet; Michael Jewett; Ron Moore; Chris Morash; Bobby Shayegan; Geoffrey Gotto; Neil Fleshner; Fred Saad; D Robert Siemens
Journal:  Can Urol Assoc J       Date:  2016-02-08       Impact factor: 1.862

Review 6.  Screening for bladder cancer: a perspective.

Authors:  Yair Lotan; Robert S Svatek; Núria Malats
Journal:  World J Urol       Date:  2007-11-21       Impact factor: 4.226

Review 7.  The health economics of bladder cancer: a comprehensive review of the published literature.

Authors:  Marc F Botteman; Chris L Pashos; Alberto Redaelli; Benjamin Laskin; Robert Hauser
Journal:  Pharmacoeconomics       Date:  2003       Impact factor: 4.981

8.  Isomorphic red blood cells using automated urine flow cytometry is a reliable method in diagnosis of bladder cancer.

Authors:  Satoru Muto; Syo-Ichiro Sugiura; Akiko Nakajima; Akira Horiuchi; Masahiro Inoue; Keisuke Saito; Shuji Isotani; Raizo Yamaguchi; Hisamitsu Ide; Shigeo Horie
Journal:  Int J Clin Oncol       Date:  2013-10-09       Impact factor: 3.402

Review 9.  Molecular screening for bladder cancer: progress and potential.

Authors:  Anirban P Mitra; Richard J Cote
Journal:  Nat Rev Urol       Date:  2010-01       Impact factor: 14.432

10.  Bladder tumor in women with microscopic hematuria: an Iranian experience and a review of the literature.

Authors:  Shahin Abbaszadeh; Saeed Taheri; Mohammad Hossein Nourbala
Journal:  Adv Urol       Date:  2009-07-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.